

## NFL BIOSCIENCES: INITIATION OF ANALYST COVERAGE BY PORTZAMPARC - BNP PARIBAS GROUP

**NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, announces today that Portzamparc - BNP Paribas Group has initiated analyst coverage of its share.**

Portzamparc - BNP Paribas Group has begun monitoring the stock, with a Buy recommendation and a target price of €4.20. The study is entitled: "Botanical medicines for addiction".

This initiation of coverage comes at a time when NFL Biosciences:

- has obtained promising results from its Phase 2a study on its NFL-101 drug candidate for smoking cessation on smokers who do not wish to stop smoking (PRECESTO);
- as part of a complementary study on the mechanism of action of NFL-101 conducted with the CEA (the French Atomic Energy and Alternative Energies Commission), demonstrated the ability of NFL-101 to reduce the irrepensible desire to smoke ('craving') by restoring normal cerebral activity in the region of the brain associated with this desire, and a targeted and specific action;
- is continuing its Phase 2b study on 318 smokers wishing to stop smoking, in 9 clinical investigation centers in France, with final results after 12 months of treatment expected at the end of July 2024;
- filed a pre-IND application with the FDA in the United States to formalize the development program for NFL-301, its drug candidate for reducing alcohol consumption.

NFL Biosciences is also covered by Invest Securities.

**Next publication:** 2023 annual results on March 29, 2024 after close of trading.

### *About NFL Biosciences*

---

NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.

The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at [www.nflbiosciences.com](http://www.nflbiosciences.com)

---

### *Contacts*

---

Bruno Lafont – [info@nflbiosciences.com](mailto:info@nflbiosciences.com) - 04 11 93 76 67

Agence Calyptus – [nflbio@calyptus.net](mailto:nflbio@calyptus.net) - 01 53 65 68 68